Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
2.2 USD | +3.29% | -20.86% | +71.88% |
Kurzporträt
Mitarbeiterzahl: 30
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 04.01.16 |
Preston Klassen
PSD | President | 55 | 22.06.23 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 30.08.19 |
Chief Tech/Sci/R&D Officer | - | 29.11.22 | |
Rekha Garg
LAW | General Counsel | - | 29.11.22 |
Amin Kamel
PRN | Corporate Officer/Principal | - | 02.06.22 |
Daniel Penksa
AUD | Comptroller/Controller/Auditor | 39 | 01.06.15 |
Christopher Aker
LAW | General Counsel | 63 | 19.05.11 |
Brian K. Campion
PRN | Corporate Officer/Principal | - | 01.07.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 01.06.17 |
David Baltimore
BRD | Director/Board Member | 86 | 01.01.09 |
Director/Board Member | 75 | 01.04.13 | |
Chairman | 74 | 01.01.08 | |
Jake Nunn
BRD | Director/Board Member | 54 | 11.06.19 |
Alice S. Huang
BRD | Director/Board Member | 85 | 26.01.21 |
Hugh Rosen
BRD | Director/Board Member | 64 | 02.06.16 |
Joseph Hagan
CEO | Chief Executive Officer | 55 | 04.01.16 |
Preston Klassen
PSD | President | 55 | 22.06.23 |
Director/Board Member | 56 | 17.04.18 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 3 725 720 | 0 | 0 | 96,25 % |
Aktie B | 0 | 258 707 | 0 | 0 | |
Aktie C | 0 | 1 330 832 | 0 | 0 | |
Aktie D | 1 | 65 465 251 | 64 540 836 ( 98,59 %) | 0 | |
Aktie E | 0 | 256 700 | 0 | 0 |
Unternehmenskontakt
Regulus Therapeutics, Inc.
4224 Campus Point Court Suite 210
92121, San Diego
+858 202 6300
http://www.regulusrx.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+71.88% | 144 Mio. | |
+2.49% | 96.73 Mrd. | |
-0.20% | 21.31 Mrd. | |
-16.61% | 21.21 Mrd. | |
-5.48% | 18.79 Mrd. | |
-42.14% | 16.37 Mrd. | |
-27.40% | 13.68 Mrd. | |
+1.44% | 13.44 Mrd. | |
+21.29% | 10.98 Mrd. | |
-21.79% | 8.56 Mrd. |
- Börse
- Aktien
- A3DNZ4 Aktie
- Unternehmen Regulus Therapeutics Inc.